CIGNA Co. (NYSE:CI) – Research analysts at Oppenheimer issued their Q1 2019 EPS estimates for CIGNA in a research report issued on Tuesday. Oppenheimer analyst M. Wiederhorn forecasts that the health services provider will post earnings per share of $3.27 for the quarter. Oppenheimer also issued estimates for CIGNA’s Q2 2019 earnings at $3.30 EPS, Q3 2019 earnings at $3.21 EPS, Q4 2019 earnings at $2.69 EPS and FY2019 earnings at $12.47 EPS.
A number of other research firms have also weighed in on CI. ValuEngine raised CIGNA from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Goldman Sachs Group began coverage on CIGNA in a report on Wednesday, January 3rd. They set a “neutral” rating and a $247.00 target price for the company. BMO Capital Markets began coverage on CIGNA in a report on Monday, October 16th. They set a “market perform” rating and a $210.00 target price for the company. Morgan Stanley lifted their target price on CIGNA from $195.00 to $223.00 and gave the company an “overweight” rating in a report on Friday, November 3rd. Finally, Citigroup lifted their target price on CIGNA from $198.00 to $231.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $205.18.
Shares of CIGNA (NYSE:CI) traded down $0.70 on Wednesday, reaching $219.66. The company had a trading volume of 1,380,058 shares, compared to its average volume of 1,185,717. CIGNA has a 52 week low of $133.52 and a 52 week high of $221.13. The stock has a market cap of $54,100.00, a price-to-earnings ratio of 24.06, a P/E/G ratio of 1.43 and a beta of 0.51. The company has a current ratio of 0.39, a quick ratio of 0.39 and a debt-to-equity ratio of 0.37.
CIGNA (NYSE:CI) last announced its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.47. CIGNA had a return on equity of 18.85% and a net margin of 5.74%. The company had revenue of $10.38 billion during the quarter, compared to analyst estimates of $10.17 billion. During the same quarter last year, the firm posted $1.94 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis.
Institutional investors and hedge funds have recently modified their holdings of the company. Saratoga Research & Investment Management bought a new stake in CIGNA in the 3rd quarter worth approximately $112,000. Capstone Investment Advisors Netherlands B.V. bought a new stake in CIGNA in the 2nd quarter worth approximately $106,000. Horan Capital Advisors LLC. bought a new stake in CIGNA in the 3rd quarter worth approximately $123,000. Grove Bank & Trust lifted its position in CIGNA by 171.9% in the 3rd quarter. Grove Bank & Trust now owns 976 shares of the health services provider’s stock worth $182,000 after buying an additional 617 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new stake in CIGNA in the 3rd quarter worth approximately $185,000. Hedge funds and other institutional investors own 87.75% of the company’s stock.
In other news, EVP Alan Muney sold 15,345 shares of CIGNA stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $200.80, for a total transaction of $3,081,276.00. Following the completion of the sale, the executive vice president now owns 28,457 shares in the company, valued at approximately $5,714,165.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William D. Zollars sold 212 shares of CIGNA stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $205.68, for a total value of $43,604.16. Following the sale, the director now owns 13,500 shares of the company’s stock, valued at approximately $2,776,680. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,556 shares of company stock valued at $14,160,975. Corporate insiders own 1.30% of the company’s stock.
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.